Menopause at Work: Silence Is Not a Strategy

Menopause at Work: When half your workforce will experience it, not talking about it isn’t neutral. It’s a leadership decision.

Modern workplaces are obsessed with optimization. Workflows, meetings, dashboards, performance metrics, quarterly reviews, sprint retros — there is a named process and a shared vocabulary for almost everything. Except for one of the most common health transitions half the workforce will experience. On that, most organizations still default to silence.

The silence isn’t accidental. It’s the accumulated result of many small choices — not to bring it up in a meeting, not to name it in a policy, not to train managers on it, not to acknowledge it in a leadership development curriculum. Individually, each of those omissions feels neutral. Collectively, they add up to an active organizational stance: we have decided this is not something we talk about here.

Women Have Already Stopped Being Quiet

Outside the workplace, the conversation has moved. HRT, lifestyle interventions, peptides, cognitive-behavioral approaches, wearable tracking, specialized telehealth — the treatment landscape is expanding at a pace no one predicted five years ago. That expansion is a market signal, and the signal is unambiguous: women are no longer willing to silently endure symptoms that affect their health, their confidence, and their careers.

Which treatment someone chooses is a personal medical decision. That isn’t the point employers need to focus on. The point is that women are actively pursuing care, actively naming the transition, and actively expecting the same workplace acknowledgment they’d receive for any other significant health condition.

What Women Are Actually Asking For

It’s important to be precise about the ask, because “menopause support” is often heard as something more than it is. Women are not asking for special treatment. They are asking for:

• The same understanding given to any employee managing a health condition that affects performance
• The same accommodation process available for other episodic or chronic conditions
• The same acknowledgment from managers that they’d offer a colleague recovering from surgery, managing migraines, or navigating a mental health diagnosis
• Permission to be honest about what they’re experiencing without paying a professional price for the honesty

That’s not a special exception. It’s equity with how the organization already handles every other legitimate health issue.

What Silence Actually Costs

The organization that stays silent doesn’t stay neutral. It quietly pays for the silence in the same ledger it uses for every other operational risk:

• Retention — experienced women stepping back, going part-time, or leaving entirely rather than explaining what they can’t safely explain
• Productivity — symptoms managed privately during meetings that should have been fully engaged with
• Culture — the signal, unmistakable to every employee, that some health issues are legitimate and others are not
• Leadership pipeline — the women who might have become senior leaders opting out at exactly the age they’d have moved into those roles

Half the Workforce

This is the number worth sitting with. Roughly half of every workforce will experience menopause. It is not a rare condition, not a minority experience, and not a demographic footnote. Choosing silence about something that will affect half of every team at some point is a strategic choice with predictable consequences — on retention, on culture, and on the caliber of leadership an organization is able to build over time.

The question isn’t whether menopause belongs in the workplace conversation. It’s already there, being managed privately by the people around you. The question is whether your leadership team is prepared to make it a conversation the organization has openly — or whether the silence continues, and gets billed to a different line item.